How long should we allow metformin to remain the bogeyman in CKD? Should MALA scare us from ever letting our patients benefit from metformin? Join us as we discuss some rare prospective data on metformin in moderate to severe CKD.
This week, we will discuss the CREDENCE trial, simply the most important nephrology trial in a generation.
This week we look at the treatment of depression in hemodialysis patients. It is cognitive behavorial therapy versus sertraline.